These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 21747745)

  • 1. Plitidepsin has a safe cardiac profile: a comprehensive analysis.
    Soto-Matos A; Szyldergemajn S; Extremera S; Miguel-Lillo B; Alfaro V; Coronado C; Lardelli P; Roy E; Corrado CS; Kahatt C
    Mar Drugs; 2011; 9(6):1007-1023. PubMed ID: 21747745
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase I clinical and pharmacokinetic study of plitidepsin as a 1-hour weekly intravenous infusion in patients with advanced solid tumors.
    Izquierdo MA; Bowman A; García M; Jodrell D; Martinez M; Pardo B; Gómez J; López-Martin JA; Jimeno J; Germá JR; Smyth JF
    Clin Cancer Res; 2008 May; 14(10):3105-12. PubMed ID: 18483378
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase I-II study of plitidepsin and dacarbazine as first-line therapy for advanced melanoma.
    Plummer R; Lorigan P; Brown E; Zaucha R; Moiseyenko V; Demidov L; Soriano V; Chmielowska E; Andrés R; Kudryavtseva G; Kahatt C; Szyldergemajn S; Extremera S; de Miguel B; Cullell-Young M; Calvert H
    Br J Cancer; 2013 Sep; 109(6):1451-9. PubMed ID: 23989947
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase I dose-escalation study of plitidepsin in combination with bevacizumab in patients with refractory solid tumors.
    Aspeslagh S; Awada A; S Matos-Pita A; Aftimos P; Bahleda R; Varga A; Soria JC
    Anticancer Drugs; 2016 Nov; 27(10):1021-7. PubMed ID: 27610894
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A phase I and pharmacokinetic study of plitidepsin in children with advanced solid tumours: an Innovative Therapies for Children with Cancer (ITCC) study.
    Geoerger B; Estlin EJ; Aerts I; Kearns P; Gibson B; Corradini N; Doz F; Lardelli P; Miguel BD; Soto A; Prados R; Vassal G
    Eur J Cancer; 2012 Feb; 48(3):289-96. PubMed ID: 22119199
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Outcomes and clinical characteristics of the compassionate use of plitidepsin in COVID-19 patients with solid tumours, haematological malignancies or anti-CD20 antibody treatment.
    Aguareles J; Villares Fernández P; Forné C; Martí-Ballesteros EM; Pradillo Fernández V; Sotres-Fernandez G; de la Fuente-Burguera A; Navarro-San Francisco C; Buzón-Martín LM; García-Delangue T; Aiello FT; Carnevali-Ruiz D; Lloris R; Luepke-Estefan XE; López-Martín JA; Jimeno JM; García-Casas A; Guisado-Vasco P
    Infect Dis (Lond); 2024 Jul; 56(7):575-580. PubMed ID: 38743059
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase II clinical and pharmacokinetic study of plitidepsin 3-hour infusion every two weeks alone or with dexamethasone in relapsed and refractory multiple myeloma.
    Mateos MV; Cibeira MT; Richardson PG; Prosper F; Oriol A; de la Rubia J; Lahuerta JJ; García-Sanz R; Extremera S; Szyldergemajn S; Corrado C; Singer H; Mitsiades CS; Anderson KC; Bladé J; San Miguel J
    Clin Cancer Res; 2010 Jun; 16(12):3260-9. PubMed ID: 20530693
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Plitidepsin: design, development, and potential place in therapy.
    Alonso-Álvarez S; Pardal E; Sánchez-Nieto D; Navarro M; Caballero MD; Mateos MV; Martín A
    Drug Des Devel Ther; 2017; 11():253-264. PubMed ID: 28176904
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Preclinical and randomized phase I studies of plitidepsin in adults hospitalized with COVID-19.
    Varona JF; Landete P; Lopez-Martin JA; Estrada V; Paredes R; Guisado-Vasco P; Fernandez de Orueta L; Torralba M; Fortun J; Vates R; Barberan J; Clotet B; Ancochea J; Carnevali D; Cabello N; Porras L; Gijon P; Monereo A; Abad D; Zuñiga S; Sola I; Rodon J; Vergara-Alert J; Izquierdo-Useros N; Fudio S; Pontes MJ; de Rivas B; Giron de Velasco P; Nieto A; Gomez J; Aviles P; Lubomirov R; Belgrano A; Sopesen B; White KM; Rosales R; Yildiz S; Reuschl AK; Thorne LG; Jolly C; Towers GJ; Zuliani-Alvarez L; Bouhaddou M; Obernier K; McGovern BL; Rodriguez ML; Enjuanes L; Fernandez-Sousa JM; Krogan NJ; Jimeno JM; Garcia-Sastre A
    Life Sci Alliance; 2022 Apr; 5(4):. PubMed ID: 35012962
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Population pharmacokinetics meta-analysis of plitidepsin (Aplidin) in cancer subjects.
    Nalda-Molina R; Valenzuela B; Ramon-Lopez A; Miguel-Lillo B; Soto-Matos A; Perez-Ruixo JJ
    Cancer Chemother Pharmacol; 2009 Jun; 64(1):97-108. PubMed ID: 18941750
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase II randomized study of Plitidepsin (Aplidin), alone or in association with L-carnitine, in patients with unresectable advanced renal cell carcinoma.
    Schöffski P; Guillem V; Garcia M; Rivera F; Tabernero J; Cullell M; Lopez-Martin JA; Pollard P; Dumez H; del Muro XG; Paz-Ares L
    Mar Drugs; 2009; 7(1):57-70. PubMed ID: 19370171
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase II study of plitidepsin in pretreated patients with locally advanced or metastatic non-small cell lung cancer.
    Peschel C; Hartmann JT; Schmittel A; Bokemeyer C; Schneller F; Keilholz U; Buchheidt D; Millan S; Izquierdo MA; Hofheinz RD
    Lung Cancer; 2008 Jun; 60(3):374-80. PubMed ID: 18054408
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Multicenter phase II study of plitidepsin in patients with relapsed/refractory non-Hodgkin's lymphoma.
    Ribrag V; Caballero D; Fermé C; Zucca E; Arranz R; Briones J; Gisselbrecht C; Salles G; Gianni AM; Gomez H; Kahatt C; Corrado C; Szyldergemajn S; Extremera S; de Miguel B; Cullell-Young M; Cavalli F
    Haematologica; 2013 Mar; 98(3):357-63. PubMed ID: 23065525
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation of plitidepsin in patients with primary myelofibrosis and post polycythemia vera/essential thrombocythemia myelofibrosis: results of preclinical studies and a phase II clinical trial.
    Pardanani A; Tefferi A; Guglielmelli P; Bogani C; Bartalucci N; Rodríguez J; Extremera S; Pérez I; Alfaro V; Vannucchi AM
    Blood Cancer J; 2015 Mar; 5(3):e286. PubMed ID: 25768401
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase II study of biweekly plitidepsin as second-line therapy in patients with advanced malignant melanoma.
    Eisen T; Thomas J; Miller WH; Gore M; Wolter P; Kavan P; Martín JA; Lardelli P
    Melanoma Res; 2009 Jun; 19(3):185-92. PubMed ID: 19436178
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase I study of weekly plitidepsin as 1-hour infusion combined with carboplatin in patients with advanced solid tumors or lymphomas.
    Salazar R; Plummer R; Oaknin A; Robinson A; Pardo B; Soto-Matos A; Yovine A; Szyldergemajn S; Calvert AH
    Invest New Drugs; 2011 Dec; 29(6):1406-13. PubMed ID: 20623160
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Plitidepsin cellular binding and Rac1/JNK pathway activation depend on membrane cholesterol content.
    Suárez Y; González-Santiago L; Zarich N; Dávalos A; Aranda JF; Alonso MA; Lasunción MA; Rojas JM; Muñoz A
    Mol Pharmacol; 2006 Nov; 70(5):1654-63. PubMed ID: 16928956
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Trabectedin has a low cardiac risk profile: a comprehensive cardiac safety analysis.
    Lebedinsky C; Gómez J; Park YC; Nieto A; Soto-Matos A; Parekh T; Alfaro V; Roy E; Lardelli P; Kahatt C
    Cancer Chemother Pharmacol; 2011 Nov; 68(5):1223-31. PubMed ID: 21416137
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Plitidepsin has a dual effect inhibiting cell cycle and inducing apoptosis via Rac1/c-Jun NH2-terminal kinase activation in human melanoma cells.
    Muñoz-Alonso MJ; González-Santiago L; Zarich N; Martínez T; Alvarez E; Rojas JM; Muñoz A
    J Pharmacol Exp Ther; 2008 Mar; 324(3):1093-101. PubMed ID: 18089842
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase I trial of the histone deacetylase inhibitor, depsipeptide (FR901228, NSC 630176), in patients with refractory neoplasms.
    Sandor V; Bakke S; Robey RW; Kang MH; Blagosklonny MV; Bender J; Brooks R; Piekarz RL; Tucker E; Figg WD; Chan KK; Goldspiel B; Fojo AT; Balcerzak SP; Bates SE
    Clin Cancer Res; 2002 Mar; 8(3):718-28. PubMed ID: 11895901
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.